deCODE genetics, Inc. Announces Sale of Its Icelandic Human Genetics Unit deCODE genetics ehf

REYKJAVIK, Iceland, Jan. 21 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. today announced that it has completed the previously-announced sale of its Iceland-based subsidiary deCODE genetics ehf (also known as Islensk erfdagreining) and its drug discovery and development programs to Saga Investments LLC, a private company. The sale followed approval by the U.S. Bankruptcy Court for the District of Delaware in deCODE genetics Inc.'s ongoing proceeding under Chapter 11 of the U.S. Bankruptcy Code. Under its new owners, deCODE genetics ehf will continue its human genetics operations and all of the deCODE brand products and services, including management of its population genetics resources.

Any statements contained in this presentation that relate to future plans, events or performance of DGI Resolution, Inc. (DGIR, formerly deCODE genetics, Inc.) are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding DGIR's expectations concerning the bankruptcy process and could differ materially from those anticipated in the forward-looking statements as a result of risks and uncertainties associated with that process, including, without limitation, (1) the ability of DGIR to obtain court approval of its motions in the Chapter 11 proceeding; (2) the uncertainty associated with motions by third parties in the bankruptcy proceeding; and (3) other risks identified in DGIR's filings with the Securities and Exchange Commission. DGIR undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

DGI Resolution, Inc.